Model performance of the final model, demonstrated by comparison of predicted to observed asunercept serum concentration-time profiles of all healthy volunteers that participated in the Phase I study APG101_CD_001 and showed asunercept concentrations above the lower limit of quantification.
continued... 
Linear Pharmacokinetics of Asunercept
The mean asunercept serum concentrations per dosing group of the dose escalation Phase I study APG101_CD_001 show linear, dose proportional pharmacokinetics of asunercept for single dose intravenous administration of 0.2 mg/kg to 20.0 mg/kg asunercept to healthy volunteers. The asunercept serum concentrations of the two groups receiving lower doses of 0.008 mg/kg and 0.04 mg/kg asunercept were below the lower limit of quantification. 
Sensitivity Analysis
Sensitivity of the final PBPK model to single parameters (local sensitivity analysis) was calculated, measured as relative change of the AUC at steady-state (week 15) of a 400 mg asunercept QW dosing regimen, using a sialic acid:glycan ratio of 0.64 for asunercept. Sensitivity analysis was carried out with a variation range of 0.1 and number of steps of 2. Using a variation range of 1.0 gave very similar results. Parameters were included into the analysis if they have been optimized (FcRn Kd (lysosomal) , CD95L Kd, CD95L koff, ASGR clearance), if they are associated with optimized parameters or if they might have a strong impact due to calculation methods used in the model. Sensitivity to a parameter was calculated as the ratio of the relative change of the simulated AUC to the relative variation of the parameter around its value used in the final model according to:
with S = sensitivity of the AUC to the examined model parameter, ΔAUC = change of the AUC, AUC = simulated AUC with the original parameter value, Δp = change of the examined parameter value, p = original parameter value. A sensitivity of + 1.0 signifies that a 10% increase of the examined parameter value causes a 10% increase of the simulated AUC. 
Dose Recommendations: Predicted First Dose AUC and Cmax Values
The asunercept dose recommendations were optimized to generate the same asunercept serum concentrations-time profiles and steady-state AUC values in the pediatric age groups as have been observed in the adult reference population of study APG101_CD_002. The simulated steady-state AUC and Cmax values using either 5.2 mg/kg asunercept QW for all age groups or the recommended doses are shown in Figure 7 of the main document, the simulated first dose AUC and Cmax values using these regimens are illustrated below. Figure S6 . Population predicted asunercept first dose AUC and Cmax values following administration of 5.2 mg/kg asunercept (left panel) or of the recommended doses (right panel) to children of different age groups. The boxes show population medians, 25 th and 75 th percentiles, the whiskers represent the most extreme data points not considered outliers. The dark green lines and shaded green areas illustrate the median and 25 th to 75 th percentile interval of the adult reference population of the Phase II study APG101_CD_002. Simulations were conducted using a sialic acid:glycan ratio of 0.64 for asunercept.
